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Teresa S.M. Tsang, MDSEE PAGE 1119E chocardiography-guided pericardiocentesiswasdeveloped in the late 1970s with the introduc-tion of 2-dimensional echocardiographic tech-
nology (1). This now widely used technique (1,2),
pioneered by Dr. James Seward and colleagues at the
Mayo Clinic, evolved with clinical testing over time
in the Mayo echocardiography laboratory. The tech-
nique of echocardiography-guided pericardiocentesis,
reﬁned over a period of >20 years at the Mayo Clinic
(3), involves the use of 2-dimensional echocardiogra-
phy to guide the selection of the best window and tra-
jectory for needle entry. The technique emphasizes
identifying the entry site closest to the body surface
and attaining maximal ﬂuid collection (1). The safety
and efﬁcacy of the technique were established in the
largest series from the Mayo Clinic, which included
1,127 consecutive procedures over 21 years (3). Patient
outcomes were also differentially evaluated and
described for patients with idiopathic effusions (4),
in those with post-operative effusions (5), in rescue
situations when tamponade occurs during coronary
intervention and electrophysiological studies (6), in
pediatric cases (7), in outpatient series (8), and in the
largest series of malignant pericardial effusions (9).
The American Society of Echocardiography endorsed
the Seward technique as the standard for echo-
cardiography-guided pericardiocentesis in its guide-
lines for echocardiography-guided interventions (2).*Editorials published in the Journal of the American College of Cardiology
reﬂect the views of the authors and do not necessarily represent the
views of JACC or the American College of Cardiology.
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PATIENTS WITH CANCER
Echocardiography-guided pericardiocentesis with
extended catheter drainage was concluded to be safe
and effective for both primary and secondary man-
agement of pericardial effusion in patients with
malignancy, on the basis of 341 procedures in 275
patients with cancer (9). Fifteen years later, the safety
and efﬁcacy of percutaneous pericardiocentesis
technique have been reconﬁrmed in a large popula-
tion of patients with cancer at the MD Anderson
Cancer Center. In this issue of the Journal, El Haddad
et al. (10) report their assessment of the outcomes of
212 patients with cancer undergoing percutaneous
pericardiocentesis. They conclude, consistent with
previous results, that the procedure is safe and efﬁ-
cacious in this population. They reconﬁrm that
extended catheter drainage reduces recurrence rates,
as demonstrated in the Mayo series (3). The data
regarding the safety of the procedure in patients with
platelet counts greater than or less than 50,000/ml are
new. The investigators conclude that the procedure
is safe even in patients with low platelet counts.Caution is warranted regarding this conclusion,
however, as the patients in the study were transfused
with platelets pre-pericardiocentesis if their platelet
counts were <50,000/ml. Therefore, platelet counts
of <50,000/ml should not be considered prohibitive if
transfusion can be done prior to pericardiocentesis. It
must also be kept in mind that many of these patients
not only had low platelet counts, but their platelet
function may have been compromised by chemo-
therapy or by concomitant therapies. Many pericar-
dial effusions in patients with cancer develop
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critical hemodynamic compromise that calls for im-
mediate pericardiocentesis. Guidelines have been
established on the basis of a meta-analysis of
clinical trials of platelet transfusion for different
procedures (11). For minimally or moderately inva-
sive procedures, the threshold for platelet trans-
fusion differs. Consideration of platelet transfusion
is necessary if the clinical scenario permits pro-
phylactic transfusion and the balance of risks and
beneﬁts for the particular case warrants it. There
may be situations of severe hemodynamic instability
in which expedient action is lifesaving. It is generally
agreed that platelet counts <20,000/ml are critically
low, making any invasive procedures unsafe without
platelet transfusion.
In the Mayo series, the optimal entry site was
located on the chest wall in 79% of cases, with the vast
majority of these being para-apical approaches; a few
were parasternal, axillary, or posterolateral (3), and
only 18% of cases involved a subcostal approach. This
contrasts substantially with the distribution of site
selection in the MD Anderson Cancer Center series
(10), in which 63% of the procedures used subxiphoid
entry. In the Mayo series, the experience was that the
distance to the heart from the surface was longer from
the subxiphoid window for most patients, and the
liver was often in the path. In the present series, the
investigators classiﬁed the needle entry site as inter-
costal or subxiphoid only. The distribution of inter-
costal sites was not further elaborated. In both series,
extended catheter drainage was associated with
signiﬁcantly lower recurrence rates. It is possible that
the irritant effects of the pigtail catheter contribute to
adhesive obliteration of the pericardial space and
apposition of parietal and visceral pericardium.
PROGNOSIS OF PATIENTS WITH CANCER
WITH PERICARDIAL EFFUSIONS
It is clear from theMDAnderson Cancer Center (10) and
Mayo Clinic (9) malignant effusion series that as a
group, these patients with cancer have an exceedingly
poor prognosis. Themedian survival timewas 143 days
in the Anderson series and 135 days in the Mayo series.
In both series, bronchogenic malignancies and effu-
sions positive for malignant cells were correlates of
poorer survival. Given the poor prognosis, the less
invasive percutaneous echocardiography-guided per-
icardiocentesis, as opposed to surgical intervention,
would be preferable for most of these patients.
The Anderson series suggests catheter drainage over 3
to 5 days, which provides a reasonable compromise
between more complete drainage and increased riskfor infection. There was no infection related to the
pigtail catheter in the Mayo series. The recommenda-
tion was to leave the catheter in until <25 to 30 ml of
ﬂuid over 24 h is achieved (3).
CONTEMPORARY UNDERSTANDING AND
FUTURE RESEARCH EFFORTS
Although the technique and science of noninvasive
echocardiography-guided pericardiocentesis have
advanced over time, and safety and efﬁcacy have
been established in large series, debates continue
with regard to whether the gold standard for treating
malignant effusions should be nonsurgical or surgi-
cal (12). Jama et al. (12) concluded in 2014, on the
basis of their review of the published research,
that surgical drainage is superior to nonsurgical ap-
proaches for symptomatic relief, effusion recurrence,
and morbidity, but their review did not include the
Mayo series of malignant effusions treated with
echocardiography-guided pericardial effusion (9)
and, of course, could not have included this new
series from the MD Anderson Cancer Center (10).
There is no doubt that there are situations in which
surgical approaches are the only meaningful solu-
tions. For instance, echocardiographically-guided
pericardiocentesis may be unsafe, ineffective, or
technically inaccessible for some loculated effusions,
especially posteriorly loculated ones. There may also
be patients in whom ﬂuid accumulation is recurrent
despite extended catheter drainage, in which case
the surgical approach may become necessary. In pa-
tients with tamponade from malignant effusions in
whom the prognosis is poor, a sensible decision
regarding echocardiography-guided pericardiocent-
esis versus surgical management can usually be
made on the basis of the clinical status and prognosis
of the patient, echocardiographic ﬁndings in terms of
effusion size and location, and the feasibility and
safety of the percutaneous versus the surgical
approach.
Data are sparse in terms of best management
practices for patients with less than large pericardial
effusions and without evidence of tamponade. Two-
dimensional and Doppler echocardiography can
deﬁne a spectrum of effusion hemodynamic param-
eters, from gross tamponade with chamber collapse
and swinging heart to more subtle states of raised
intrapericardial pressure with only early Doppler
ﬁndings of hemodynamic signiﬁcance or no deﬁnite
evidence for any raised intrapericardial pressures.
The point at which intervention is necessary remains
contentious. The individualized decision comes down
to a balance of risk and beneﬁt to a speciﬁc patient.
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1131The majority of pericardial effusions in patients with
malignancies have accumulated over time, and pa-
tients usually do not present in dire, hemodynami-
cally unstable states. For pericardial effusions related
to pericarditis without tamponade, anti-inﬂammatory
therapies, including nonsteroidal anti-inﬂammatory
drugs and colchicine, have been used for medical
management. Data regarding medical management or
drug therapy for malignant effusions are practically
nonexistent. Further research is warranted.
In summary, echocardiography-guided pericardio-
centesis with extended catheter drainage has stood
the test of time in terms of safety and efﬁcacy. On thebasis of the totality of evidence, and our knowledge,
minimally invasive echocardiography-guided peri-
cardiocentesis with extended catheter drainage
should be considered the treatment of choice for most
patients with cancer, and surgical options should be
reserved for effusions with anatomy that is not
amenable to such an approach or for patients in whom
effusions recur despite adequate catheter drainage.
REPRINT REQUESTS AND CORRESPONDENCE: Dr.
Teresa S.M. Tsang, University of British Columbia,
2775 Laurel Street, Vancouver, British Columbia V5Z
1M9, Canada. E-mail: t.tsang@ubc.ca.RE F E RENCE S1. Tsang TS, Freeman WK, Sinak LJ, et al. Echo-
cardiographically guided pericardiocentesis: evo-
lution and state-of-the-art technique. Mayo Clin
Proc 1998;73:647–52.
2. Silvestry FE, Kerber RE, Brook MM, et al.
Echocardiography-guided interventions. J Am Soc
Echocardiogr 2009;22:213–31.
3. Tsang TSM, Enriquez-Sarano M, Freeman WK,
et al. Consecutive 1127 therapeutic echo-
cardiographically guided pericardiocenteses:
clinical proﬁle, practice patterns, and outcomes
spanning 21 years. Mayo Clin Proc 2002;77:
429–36.
4. Tsang TSM, Barnes ME, Gersh BJ, et al. Out-
comes of clinically signiﬁcant idiopathic pericardial
effusion requiring intervention. Am J Cardiol
2003;91:704–7.
5. Tsang TS, Barnes ME, Hayes SN, et al.
Clinical and echocardiographic characteristics ofsigniﬁcant pericardial effusions following
cardiothoracic surgery and outcomes of echo-
guided pericardiocentesis for management:
Mayo Clinic experience 1979-1998. Chest 1999;
116:322–31.
6. Tsang TS, Freeman WK, Barnes ME, et al.
Rescue echocardiographically guided peri-
cardiocentesis for cardiac perforation complicating
catheter-based procedures. The Mayo Clinic
experience. J Am Coll Cardiol 1998;32:1345–50.
7. Tsang TS, El-Najdawi EK, Seward JB, et al.
Percutaneous echocardiographically guided peri-
cardiocentesis in pediatric patients: evaluation of
safety and efﬁcacy. J Am Soc Echocardiogr 1998;
11:1072–7.
8. Drummond JB, Seward JB, Tsang TS, et al.
Outpatient two-dimensional echocardiography-
guided pericardiocentesis. J Am Soc Echocardiogr
1998;11:433–5.9. Tsang TS, Seward JB, Barnes ME, et al. Out-
comes of primary and secondary treatment of
pericardial effusion in patients with malignancy.
Mayo Clin Proc 2000;75:248–53.
10. El Haddad D, Iliescu C, Yusuf SW, et al.
Outcomes of cancer patients undergoing percu-
taneous pericardiocentesis for pericardial effusion.
J Am Coll Cardiol 2015;66:1119–28.
11. Kaufman RM, Djulbegovic B, Gernsheimer T, et al.
Platelet transfusion: a clinical practice guideline from
the AABB. Ann Intern Med 2015;162:205–13.
12. Jama GM, Scarci M, Bowden J, Marciniak SJ.
Palliative treatment for symptomatic malignant
pericardial effusion. Interact Cardiovasc Thorac
Surg 2014;19:1019–26.KEY WORDS echocardiography,
pericardial effusions, pericardiocentesis
